Naringenin and epigallocatechin-3-gallate decreased the BCL-2 expression accordingly in gastric cancer (SGC-7901) cells [104] and in cholangiocarcinoma (HuCC-T1) cells [172]. The gene discussed is BCL2; the disease is gastric cancer.